- Home
- » Tags
- » Glycoprotein 130
Top View
- Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance
- UC San Francisco Electronic Theses and Dissertations
- Mesenchymal Stem Cells Secretory Responses: Senescence Messaging Secretome and Immunomodulation Perspective
- And Anti-Inflammatory Properties of the Cytokine Interleukin-6
- The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes
- 1730.Full.Pdf
- IL-6-Mediated Environmental Conditioning of Defective Th1 Differentiation Dampens Antitumour Immune Responses in Old Age
- Characterization of a Gp130 Signaling Receptor Polymorphism
- Toxoplasma Gondii Glycoprotein 130 Hypermorphs to IL-6 Mediates The
- Interleukin‑6 Signalling As a Valuable Cornerstone for Molecular Medicine (Review)
- N–3 Pufas Reduce T-Helper 17 Cell Differentiation by Decreasing Responsiveness to Interleukin-6 in Isolated Mouse Splenic CD4+ T Cells1–3
- Glycoprotein 130 Receptor Signaling Mediates A-Cell Dysfunction in a Rodent Model of Type 2 Diabetes
- Interleukin-6 in Neuromyelitis Optica Spectrum Disorder Pathophysiology
- Signaling Pathways in Cancer-Associated Fibroblasts And
- Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11
- Stressor-Dependent Alterations in Glycoprotein 130: Implications for Glial Cell Reactivity, Cytokine Signaling and Ganglion Cell
- Modulation of Inflammation by Interleukin‐
- Supplementary Table S1 (Mitchell Et Al.)
- Intracellular Role of IL-6 in Mesenchymal Stromal Cell
- Interleukins and Interleukin Receptors Evolutionary History and Origin in Relation to CD4+ T Cell Evolution
- Blockade of Soluble IL-6 Receptor Governs IL-6 Activit
- Gingival Crevicular Fluid
- Improved Assembly of Bispecific Antibodies
- Therapeutic Strategies for the Clinical Blockade of IL-6/Gp130 Signaling
- Targeting the Glycoprotein 130 Receptor Subunit to Control Pain and Inflammation
- IL-1R3 Blockade Broadly Attenuates the Functions of Six Members of the IL-1 Family, Revealing Their Contribution to Models of Disease
- Nanotechnology Solutions for Controlled Cytokine Delivery: an Applied Perspective
- Activated Gp130 Signaling Selectively Targets B Cell Differentiation to Induce Mature Lymphoma and Plasmacytoma
- ( 12 ) United States Patent
- Persistent Loss of IL-27 Responsiveness in CD8+ Memory T Cells Abrogates IL-10 Expression in a Recall Response
- Inflammation, Immune Response, and Fibrosis
- Interleukin-6 As a Therapeutic Target Jean-Francois¸ Rossi1,2,3, Zhao-Yang Lu4, Michel Jourdan2, and Bernard Klein2,3